Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | MEN1 | O00255 | 6/20 | 0.39 |
| ▸ | POLB | P06746 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | CCR6 | P51684 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | MGAM | O43451 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1137916 | 0.89 | MAPT (0.40) | MAPTKMT2AALDH1A1MEN1POLB | |
| Hydrochloric Acid SCHEMBL28409932 | 0.87 | MAPT (0.39) | MAPTKMT2AALDH1A1MEN1POLB | |
| SCHEMBL29161382 | 0.75 | MAPT (0.54) | MAPTKMT2AALDH1A1MEN1POLB | |
| SCHEMBL6866011 | 0.74 | IDO1 (0.39) | MAPTKMT2AALDH1A1MEN1POLB | |
| SCHEMBL10908259 | 0.73 | NPC1 (0.42) | MAPTKMT2AALDH1A1MEN1POLB | |
| Isatin SCHEMBL7073534 | 0.71 | MAPT (0.47) | MAPTKMT2AALDH1A1MEN1POLB | |
| SCHEMBL5855550 | 0.71 | MAPT (0.40) | MAPTKMT2AALDH1A1MEN1POLB | |
| SCHEMBL9139763 | 0.71 | ATM (0.41) | MAPTKMT2AALDH1A1MEN1POLB | |
| SCHEMBL31513845 | 0.71 | ALDH1A1 (0.30) | MAPTALDH1A1NPSR1PKMMAPK10 | |
| SCHEMBL6866868 | 0.71 | MAPT (0.43) | MAPTKMT2AALDH1A1MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331032-B2 | Quinone reductase 2 inhibitor compounds and uses thereof | DUKE UNIVERSITY (US) | 2025-06-17 | — | — | US | disclosed |
| CN-112867711-B | Quinone reductase 2 inhibitor compounds and uses thereof | 杜克大学 | 2025-02-18 | — | — | CN | disclosed |
| JP-2025003966-A | Quinone reductase 2 inhibitor compounds and uses thereof | デューク・ユニヴァーシティ | 2025-01-14 | — | — | JP | disclosed |
| EP-3867239-B1 | QUINONE REDUCTASE 2 INHIBITOR COMPOUNDS AND USES THEREOF | UNIV DUKE (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-112823006-B | Quinone reductase 2 inhibitors as neuroprotective agents | 杜克大学 | 2024-09-17 | — | — | CN | disclosed |
| EP-3866802-B1 | QUINONE REDUCTASE 2 INHIBITORS FOR USE AS NEUROPROTECTIVE AGENTS | UNIV DUKE (US) | 2024-08-21 | — | — | EP | disclosed |
| US-11351275-B2 | Metal complexes with bisphophonate or pyrophosphate useful as imaging agents | DUKE UNIVERSITY (US) | 2022-06-07 | — | — | US | disclosed |
| US-6841555-B2 | Lavendamycin analogs, quinoline-5,8-diones and methods of using them | BALL STATE UNIVERSITY (US) | 2005-01-11 | — | — | US | disclosed |
| US-20040248922-A1 | LAVENDAMYCIN ANALOGS, QUINOLINE-5,8-DIONES AND METHODS OF USING THEM | BALL STATE UNIVERSITY | 2004-12-09 | — | — | US | disclosed |
| US-6444684-B1 | ANTIBIOTIC AND ANTI-HIV REVERSE TRANSCRIPTASE (HIV-RT) ACTIVITY; TREATING HIV INFECTION AND ALSO WITH AZT; ANTITUMOR | BALL STATE UNIVERSITY | 2002-09-03 | — | — | US | disclosed |
| US-6030983-A | ANTITUMOR AND -CARCINOGENIC AGENTS; ANTIBIOTICS; BACTERICIDES; VIRICIDES; PARACITICIDES; ENZYME INHIBITORS; POLYMERASES; FARNESYL-PROTEIN TRANSFERASE; RAS PROTEINS | BALL STATE UNIVERSITY (US) | 2000-02-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331032-B2 | Quinone reductase 2 inhibitor compounds and uses thereof | NQO1, SQOR, NQO2 | MAPT 3791/4885KMT2A 939/4885ALDH1A1 106/4885 |
| US-20040248922-A1 | LAVENDAMYCIN ANALOGS, QUINOLINE-5,8-DIONES AND METHODS OF USING THEM | LSS, CYP51A1, COX5A | MAPT 4560/4885KMT2A 1940/4885ALDH1A1 1342/4885 |
| US-11351275-B2 | Metal complexes with bisphophonate or pyrophosphate useful as imaging agents | PPIP5K2, MPI, PHPT1 | MAPT 861/4885KMT2A 3850/4885ALDH1A1 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.